Europe
Companies strengthen their leadership teams and boards of directors with this week’s slate of Movers & Shakers.
To wrap up Breast Cancer Awareness Month, BioSpace gathered some examples of recent breakthroughs in breast cancer treatment.
The agent is an antibody-based fluorescence-guided approach aimed at improving surgery and clinical outcomes.
Under the terms of the deal, Roche will pay Dicerna $200 million upfront and up to another $1.47 billion for various development, regulatory and commercial milestones.
SeraNovo B.V. announced that it has signed a License Agreement with Carna Biosciences, Inc., a company engaged in drug development specializing in the development of kinase inhibitors.
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today published positive clinical trial results from a dose-escalating Phase I/IIa trial with oncolytic virus ParvOryx in metastatic, inoperable pancreatic cancer.
Dow and Evonik have entered into an exclusive technology partnership. Together, they plan to bring a unique method for directly synthesizing propylene glycol (PG) from propylene and hydrogen peroxide to market maturity.
15,000 sq. ft of laboratory and office space at Coldham’s Business Park will enable continued growth and development of the Company’s integrated desktop platform for DNA synthesis
MorphoSys AG reported its financial results for the third quarter of 2019.
MorphoSys AG announced topline results from the primary analysis of the retrospective observational matched control cohort This study was designed to compare the effectiveness of lenalidomide monotherapy based on real-world patient data with the efficacy outcomes of the tafasitamab/lenalidomide combination, as investigated in MorphoSys’s L-MIND trial
PRESS RELEASES